NSRGY - Does Nestlé's Biotech Segment Make It a Buy?
2023-09-12 09:53:00 ET
Biotech is probably not the first, second, or third thing that comes to mind when you think of Nestlé , (OTC: NSRGY) the Swiss packaged foods juggernaut responsible for a smorgasbord of delectable treats ranging from Cheerios to KitKats and even San Pelligrino water.
So you may be surprised to hear that it also develops medicines for treating certain allergies, gastrointestinal disorders, and metabolic diseases. And you might be even more surprised to learn that the company is raking in billions from its health products and therapies.
But for a business as large as Nestlé, it's entirely possible that those billions are just drops in the bucket. So does its biotech work make this stock worth buying, or is it just an oddity created as a long shot attempt to drive growth? To answer this question, let's start by putting the issue into the proper context.
For further details see:
Does Nestlé's Biotech Segment Make It a Buy?